EXHIBIT 10(z)
ENZO DIAGNOSTICS, INC. - AMERSHAM INTERNATIONAL PLC
DISTRIBUTORSHIP AGREEMENT
THIS AGREEMENT, effective upon acceptance by both parties below by and between
ENZO DIAGNOSTICS, INC. ("ENZO"), a New York corporation having its principal
place of business at 00 Xxxxxxxxx Xxxxxxxxx, Xxxxxxxxxxx, Xxx Xxxx 00000,
U.S.A., and AMERSHAM INTERNATIONAL public limited company ("AMERSHAM") a company
incorporated in England and Wales, having its principal place of business at
Xxxxxxxx Xxxxx, Xxxxxx Xxxxxxxx, Xxxxxxxxxxxxxxx XX0 0XX, Xxxxxxx.
WHEREAS, ENZO owns rights to certain PATENTS listed in EXHIBIT A
("PATENTS");
WHEREAS ENZO manufactures and/or sells certain PRODUCTS ("PRODUCT(S)")
covered by claims of PATENTS;
WHEREAS AMERSHAM wishes to market and distribute some of said PRODUCTS
as listed in EXHIBIT B;
NOW, THEREFORE, in consideration of the good and valuable mutual
agreements hereinafter set forth, the parties hereto agree as follows:
DEFINITIONS:
AMERSHAM Affiliate means an entity controlled by or under common
control with AMERSHAM, including United States Biochemical Corporation
(USB), as listed in EXHIBIT C. For purposes of this AGREEMENT, control
shall mean the ownership of a majority of the voting equity interest.
AMERSHAM Distributor means a local company, outside the countries listed in
EXHIBIT C, in which AMERSHAM does not sell directly or through an
AMERSHAM Affiliate. AMERSHAM Distributors do not have rights to sell
in the countries listed in EXHIBIT C.
AMERSHAM means AMERSHAM International, including USB, AMERSHAM Affiliates and
AMERSHAM Distributors.
PRODUCT means an individual reagent or combination of reagents (kit) that are,
individually or combined, covered by ENZO PATENTS (EXHIBIT A) as
listed in EXHIBIT B.
COMPONENT, listed in EXHIBIT D, means a reagent that is a necessary part of the
PRODUCT.
COMPONENT 1 means a COMPONENT, as listed in EXHIBIT E, that is covered by ENZO
PATENT(S) and by AMERSHAM patent(s) either assigned or licensed to
AMERSHAM and not sublicensed to a third party for Life Science
research use (not an AMERSHAM Affiliate or AMERSHAM Distributor as
defined above and as listed in EXHIBIT C).
1. Distributor Appointment
1.1 ENZO hereby appoints AMERSHAM to act as its nonexclusive distributor
worldwide for the distribution and sale of PRODUCTS through AMERSHAM
Affiliates listed in EXHIBIT C, and AMERSHAM Distributors and AMERSHAM
agrees to act as such distributor under the terms and conditions set
forth herein.
1.2 AMERSHAM agrees:
a. not to purchase any PRODUCTS from other suppliers;
b. not to manufacture PRODUCTS, except as otherwise stated in this
AGREEMENT;
c. to rely on ENZO as its sole source of PRODUCTS;
d. not to use any PRODUCT to manufacture new products or other PRODUCTS,
except when designated by ENZO to manufacture such PRODUCTS for ENZO
as provided in Paragraph 3.3 below;
e. that all PRODUCTS sold by AMERSHAM are for research use only and are
not intended for or to be used for diagnostic or therapeutic
purposes; and
f. that except for DISTRIBUTION under the terms and conditions as set
forth in this AGREEMENT, purchase does not include any right or
license to exploit these PRODUCTS commercially, including any right
to sell these PRODUCTS to other distributors who are not AMERSHAM
Affiliates or AMERSHAM Distributors (EXHIBIT C) and
- 2 -
that any commercial use or development of these PRODUCTS without the
express written authorization of ENZO is strictly prohibited.
2. Relationship between ENZO and AMERSHAM
2.1 Nothing herein creates or constitutes a partnership or an agreement of
agency between the parties with respect to any activities whatsoever. The
relationship between ENZO and AMERSHAM shall be that of seller and buyer,
and neither party shall conclude any contract or agreement or make any
commitment, representation or warranty which binds the other party or
otherwise acts in the name of or on behalf of the other party.
2.2 This AGREEMENT may not be assigned or otherwise transferred by AMERSHAM
without the prior written consent of ENZO. Any attempted assignment or
transfer without such consent shall be void.
2.3 AMERSHAM agrees that it has manufactured and sold in the past a range of
COMPONENTS, COMPONENTS 1 and PRODUCTS and maintains in its current
inventory the aforementioned COMPONENTS, COMPONENTS 1 and PRODUCTS all as
set forth in EXHIBIT F. AMERSHAM agrees that it will * . ENZO agrees that
* will be applied as full consideration for satisfaction of damages
incurred by ENZO arising from the past manufacture, use and sale of said
COMPONENTS, COMPONENTS 1 and PRODUCTS by AMERSHAM, AMERSHAM Affiliates
and AMERSHAM Distributors.
2.4 ENZO and AMERSHAM agree that the distribution relationship between them
does not constitute, nor does it imply a license of any of ENZO's
technology or patents, nor does it abrogate any of ENZO's rights under
its patents. ENZO maintains full rights under its PATENTS. The foregoing
statements are paramount to this AGREEMENT.
3. PRODUCTS, Price and Payment
3.1 PRODUCTS covered by this Agreement are listed in EXHIBIT B attached
hereto. The price to AMERSHAM for each product shall be as listed in
----------
* The information omitted is confidential and has been filed separately with
the Commission pursuant to Rule 406.
- 3 -
EXHIBIT B. Prices are based upon *
Prices to AMERSHAM may be adjusted no more than once during a calendar
year. ENZO has the right to negotiate to adjust prices to AMERSHAM after
providing AMERSHAM with forty-five (45) days written notice. Any price
adjustment will affect future purchases, but will not affect those
already under existing firm purchase order commitment. AMERSHAM shall be
free to set all resale prices to its customers.
3.2 ENZO or AMERSHAM may propose in writing to add, to modify or to delete a
PRODUCT or PRODUCTS in EXHIBIT B. Both ENZO and AMERSHAM must agree to
such additions to, deletions from or modifications of PRODUCTS in EXHIBIT
B before such additions, deletions or modifications are incorporated
therein.
3.3 Upon signing of this AGREEMENT, ENZO designates AMERSHAM to
*
3.4 ENZO, may, at its discretion, and for a specified period of time,
designate AMERSHAM as an interim manufacturer to manufacture certain *
certain PRODUCTS, including the corresponding packaging, other than those
specified by Paragraph 3.3 for ENZO. These * PRODUCTS and prices to ENZO
are listed in EXHIBIT D. Upon * written notice to AMERSHAM, ENZO may
either manufacture * PRODUCT(s) or may designate an alternate
manufacturer.
3.5 Whenever prices for PRODUCTS are adjusted, prices of COMPONENTS may be
adjusted upon mutual agreement of the parties; the ratio of COMPONENT
price to PRODUCT price will not increase.
4. Terms of Payment and Audit
4.1 Net, thirty (30) days from the end of the month in which the PRODUCTS are
delivered to AMERSHAM.
----------
* The information omitted is confidential and has been filed separately with
the Commission pursuant to Rule 406.
- 4 -
4.2 Net, thirty (30) days from the end of the month in which the COMPONENTs
are delivered to ENZO.
4.3 AMERSHAM agrees to permit its books and records to be examined by ENZO on
reasonable prior notice, as necessary, but not more often than once per
year to verify receipts. Such examination is to be made by ENZO, at
ENZO's expense, except in the event that the results of the audit reveal
a discrepancy benefiting ENZO by * then the audit fees shall be paid by
AMERSHAM.
5. PRODUCT Shipments
5.1 ALL PRODUCTS shipped by ENZO to AMERSHAM will be shipped F.O.B.
Farmingdale, NY. ENZO shall ensure PRODUCTS are suitably, safely and
securely packaged and labeled before dispatch.
5.2 ALL COMPONENTS shipped by AMERSHAM to ENZO will be shipped F.O.B. Cardiff
Laboratories, Wales. AMERSHAM shall ensure COMPONENTS are suitably,
safely and securely packaged and labeled before dispatch.
6. Forecasts and Purchase Orders
6.1 AMERSHAM shall issue a forecast schedule during the mid-month of each
calendar quarter covering its estimated requirements for PRODUCTS for the
succeeding two (2) calendar quarters. Such forecast shall be considered
for planning purposes only and do not represent a purchase commitment.
6.2 A purchase order will be issued by AMERSHAM at least sixty (60) days in
advance of the requested delivery date of PRODUCT. This purchase order
will indicate specific delivery and/or shipping requirements. Purchase
orders will be delivered to ENZO by Federal Express or similar carrier so
that the receipt can be confirmed. ENZO shall meet such requirements
unless it advises AMERSHAM within * of the date of the receipt of such
purchase order that it is unable to supply PRODUCT as ordered by AMERSHAM
whereupon the parties agree to discuss a revised schedule for delivery of
PRODUCT to AMERSHAM. After ENZO and AMERSHAM have agreed to the
provisions of a revised schedule, ENZO will make its best efforts to
fulfill the provisions of the revised schedule, but if unable to do so
----------
* The information omitted is confidential and has been filed separately with
the Commission pursuant to Rule 406.
- 5 -
or if agreement on a revised schedule cannot be reached, ENZO by good
faith effort will designate AMERSHAM as an interim or temporary
manufacturer for such PRODUCT for ENZO until such time as ENZO gives
AMERSHAM written notice that ENZO is ready to recommence supply.
6.3 ENZO shall place orders for COMPONENTS within fourteen (14) days
following receipt of AMERSHAM's purchase order for PRODUCTS. COMPONENTS
shall comply with the written specification therefor supplied by AMERSHAM
with COMPONENTS. ALL OTHER WARRANTIES EXPRESS OR IMPLIED INCLUDING
WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A
PARTICULAR PURPOSE ARE HEREBY EXCLUDED.
6.4 Each purchase order shall be governed by the relevant provisions of this
AGREEMENT (unless otherwise expressly provided in the individual purchase
order and confirmed in writing by ENZO) and no term or condition which
may appear in the printed matter in AMERSHAM's order form or any form
from ENZO shall be binding on either party or apply to any transaction
under this AGREEMENT.
7. PRODUCT Deliveries and Specifications
7.1 Within about forty five (45) days after the effective date of this
AGREEMENT, ENZO and AMERSHAM shall agree on PRODUCT specifications and
package inserts for the PRODUCTS which shall otherwise be in the form set
out in EXHIBIT B. Quality Control (QC) specifications for the PRODUCTS in
EXHIBIT B, to be agreed upon by ENZO and AMERSHAM, are also listed in
EXHIBIT B.
7.2 When an order is placed by AMERSHAM, ENZO shall ship the PRODUCT in
accordance with section 5 above. Failure by AMERSHAM to notify ENZO of
rejection of the PRODUCT within * of receipt of PRODUCT will constitute
acceptance. ENZO shall supply, at the time of shipment of the PRODUCT to
AMERSHAM, a statement that the PRODUCT conforms to the PRODUCT
specifications. If after receipt of the PRODUCT, AMERSHAM determines that
it does not conform to the PRODUCT specifications provided by ENZO, and
that the failure to conform to the PRODUCT specifications was not the
result of shipping and handling or quality of COMPONENTS delivered by
AMERSHAM, AMERSHAM will provide ENZO with
----------
* The information omitted is confidential and has been filed separately with
the Commission pursuant to Rule 406.
- 6 -
documentation of this failure to conform to the PRODUCT specifications.
If ENZO accepts the documentation provided by AMERSHAM, ENZO will replace
the order. If ENZO does not accept the documentation provided by
AMERSHAM, then the differences in the determination of the manufacturing
specifications will be settled by representatives of the technical staffs
of ENZO and AMERSHAM.
7.3 If AMERSHAM receives a notice from a third party asserting that any of
the PRODUCTS infringe on an issued patent in the country in which they
are sold, then AMERSHAM shall immediately give notice to ENZO. Upon
notice to ENZO or AMERSHAM from a third party asserting that any of the
PRODUCTS of this AGREEMENT infringe on an issued patent in the country in
which such PRODUCTS are sold, ENZO has the right to exclude such PRODUCTS
from this AGREEMENT for that country and can further instruct AMERSHAM to
cease all such distribution of such PRODUCT in that country. Further
distribution of PRODUCTS after such instruction from ENZO to AMERSHAM
will be at the sole risk of AMERSHAM and AMERSHAM shall indemnify and
hold harmless ENZO from all infringement liability and damages with
respect to such PRODUCTS, including legal costs, compensatory and
punitive damages, and attorneys fees.
7.3.1 ENZO will use its best efforts to obtain a license under commercially
reasonable terms from any such third party asserting patents as described
in Paragraph 7.3. In this event ENZO has the right to adjust prices to
AMERSHAM to reflect the licensing cost and ENZO and AMERSHAM will
negotiate in good faith to arrive at the amended price.
7.3.2 In the absence of instructions from ENZO to cease sales, ENZO will
indemnify AMERSHAM against claims or proceedings for infringements.
7.3.3 Notwithstanding any third party infringement claims, all provisions of
this AGREEMENT, including Section 7, shall not be affected but shall
remain in full force and effect.
8. Sales Promotions
8.1 AMERSHAM shall use its best efforts in sales promotions and advertisement
of the PRODUCTS such as direct mailings, direct customer contact, catalog
listings and trade meeting promotions. ENZO will provide AMERSHAM with
one copy of the literature, technical data, specifications and the like
describing the PRODUCTS as they are currently produced for the assistance
of AMERSHAM in the preparation of advertising, catalog and other sales
and promotional material. AMERSHAM will list PRODUCTS in its next
available
- 7 -
or published product catalog(s) in which the PRODUCTS can be listed and
continued such listing after the effective date of this AGREEMENT.
AMERSHAM will modify the listings of PRODUCTS in its product catalog(s)
as soon as reasonably possible after any corresponding modification of
the list of such PRODUCTS in EXHIBIT B.
9. PRODUCT Warranty
9.1 ENZO warrants that the PRODUCTS sold by ENZO to AMERSHAM shall meet the
specifications accompanying the PRODUCT delivery. ENZO's sole obligation
is to replace the PRODUCTS or give credit therefor to the extent of the
purchase price. THIS WARRANTY IS EXPRESSLY IN LIEU OF ANY OTHER
WARRANTIES OR LIABILITIES, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES
OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.
9.2 ENZO further warrants that all relevant quality control tests and quality
assurance procedures will be performed for each batch of PRODUCTS so that
each batch of PRODUCT conforms with the Product Specifications as listed
in EXHIBIT B, that the PRODUCTS will be contained, packaged and labeled
as specified by the Product Specifications for such PRODUCTS and that the
PRODUCTS will comply with product safety regulations as indicated in
EXHIBIT G.
10. Storage and Stock Rotation
10.1 ENZO agrees to share with AMERSHAM all necessary storage and stock
rotation practices which apply to the PRODUCTS.
10.2 AMERSHAM further agrees to take diligent care not to ship PRODUCTS to its
customers which have expired, been damaged in storage or handling, or
improperly stored. AMERSHAM will be responsible for damages arising from
its shipment of expired, damaged, or improperly stored PRODUCTS.
- 8 -
11. PRODUCT Labels
11.1 AMERSHAM agrees to ship all PRODUCTS with a joint PRODUCT label which
prominently includes the name
ENZO DIAGNOSTICS, INC.
and
AMERSHAM INTERNATIONAL plc
with their respective company logos where appropriate. AMERSHAM further
agrees to ship all PRODUCTS intact with ENZO's package inserts and any
notice(s) appearing thereon.
12. Force Majeure
12. No liability shall result to either party from delay in performance or
from nonperformance under this AGREEMENT caused by circumstances beyond
the control of the party who has delayed performance or not performed.
The nonperforming party shall be diligent in attempting to remove any
such cause and shall promptly notify the other party of its extent and
probable duration.
13. Duration and Termination
13.1 This AGREEMENT shall become effective as of the date hereinabove written
and shall continue for a period of *. Unless terminated, it will continue
thereafter for successive renewal terms of *. Notwithstanding such period
or any renewal, either party may terminate this AGREEMENT without cause
at any time by giving the other party notice in writing at least * in
advance of the effective termination date stated in such notice.
13.2 Upon termination of this AGREEMENT all rights, including distribution
rights to AMERSHAM and AMERSHAM Affiliates and AMERSHAM Distributors
(EXHIBIT C) will be deemed canceled and returned to ENZO.
14. Confidentiality
14.1 Each party undertakes to keep secret and not disclose any information of
a confidential nature received from the other relating to the subject of
this AGREEMENT or the business affairs of the other both during and after
this
----------
* The information omitted is confidential and has been filed separately
with the Commission pursuant to Rule 406.
- 9 -
AGREEMENT. This undertaking will not apply to any such information which
is or falls into the public domain through no fault of the recipient or
is lawfully received from a third party or independently developed by the
recipient's staff without reverence to the discloser's information.
14.2 Neither party shall make any public announcement in relation to this
AGREEMENT without the prior written approval of the other or as otherwise
required by law.
15. Indemnification
15.1 Except to the extent the other is negligent or commits an act of wilful
misconduct or in default of the terms hereof, each party shall hold the
other party harmless from responsibility or liability for damages related
to the PRODUCTS or COMPONENTS of this AGREEMENT arising from the fault of
such party, its affiliated companies, or its agents or employees.
16. Notices
16.1 All notices to be given with respect to this AGREEMENT shall be in
writing and shall be deemed effectively given:
a. when delivered personally;
b. seven calendar days after being deposited in the mail, registered or
certified mail, return receipt requested;
c. when telecopied or faxed, receipt acknowledged; or
d. when telexed, confirmed;
addressed as set forth below, or to such other address that either party
designates by written notice to the other party;
ENZO: Enzo Diagnostics, Inc.
000 Xxxxx Xxxxxx, 00xx Xxxxx
Xxx Xxxx, Xxx Xxxx 00000
Attn: Xx. Xxxxxxx X. Xxxxxxxxxx
Vice President, Scientific Affairs
Fax No.: (000) 000-0000
- 10 -
AMERSHAM: AMERSHAM INTERNATIONAL PLC
Xxxxxxxx Xxxxx
Xxxxxx Xxxxxxxx
Xxxxxxxxxxxxxxx XX0 0XX
England
Att: Company Secretary
Fax No.: (494) 542266
17. Governing Law
17.1 This Agreement is made under and shall be governed by the laws of the
State of New York.
18. Waiver
18.1 Waiver by ENZO or AMERSHAM of any provision of this AGREEMENT shall not
be deemed a waiver of future compliance therewith and such provision as
well as all other provisions hereunder shall remain in full force and
effect.
19. Compliance with Laws
19.1 Each party will comply with all United States laws, ordinances and
regulations properly applicable to the manufacture, sale and distribution
of the PRODUCTS described herein.
20. Headings and Numbers
20.1 All Headings and Numbers of the clauses of this AGREEMENT are inserted
for convenience only and shall not affect any construction or
interpretation of this AGREEMENT.
21. Severability
21.1 IN THE EVENT that any clause of this Agreement shall be found to be void
or unenforceable, such finding shall not be construed to render any other
clause of this AGREEMENT either void or unenforceable, and all other
clauses shall remain in full force and effect unless the clause(s) which
is/are invalid or unenforceable shall substantially affect the rights or
obligations granted to or undertaken by either party.
- 11 -
22. Entirety
22.1 THIS AGREEMENT together with the EXHIBITS attached hereto embodies the
entire understanding between AMERSHAM and ENZO, and there are no
contracts or prior drafts of the Agreement, understandings, conditions,
warranties or representations, oral or written, express or implied, with
reference to the subject matter hereof which are not merged herein.
Except as otherwise specifically stated, no modification here to shall be
of any force or effect unless (1) reduced to writing and signed by both
parties hereto, and (2) expressly referred to as being modifications of
this AGREEMENT.
IN WITNESS, WHEREOF, the parties have caused this AGREEMENT to be
executed by their duly authorized representatives.
ENZO DIAGNOSTICS, INC. AMERSHAM INTERNATIONAL PLC
By: By:
------------------------------ ----------------------------------
Xxxxxx Xxxxxxx ((name))
Title: President Title: Commercial Director
--------------------------- ---------------------------
Date: Feb 16 1995 Date: 21. 2. 95
--------------------------- ---------------------------
* * * * * * *
- 12 -
EXHIBIT A
Enzo Diagnostics, Inc. Issued Patents
U.S. Patents
================================================================================
Grant of
Patent
Patent Number Title/Inventor Issue Date
--------------------------------------------------------------------------------
4,687,732 Visualization Polymers and Their Aug. 18, 1987
Application to Diagnostic Medicine
Xxxxx X. Xxxx et al.
--------------------------------------------------------------------------------
4,707,352 Method of Radioactively Labeling Nov. 17, 1987
Diagnostic and Therapeutic Agents
Containing a Chelating Group
Xxxxxx X. Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
4,707,440 Nucleic Acid Hybridization Assay and Nov. 17, 1987
Detectable Molecules Useful in Such Assay
Xxxxxx X. Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
4,711,955 Modified Nucleotides and Methods of Dec. 8, 1987
Preparing and Using Same
Xxxxx X. Xxxx et al.
--------------------------------------------------------------------------------
4,746,604 Specific Binding Assays Utilizing A Viable May 24, 1988
Cell as a Label
Xxxxxxx Xxxxxxxxxx
--------------------------------------------------------------------------------
4,755,458 Composition and Method for the Detection Jul. 5, 1988
of the Presence of a Polynucleotide
Sequence of Interest
Xxxxxx Xxxxxxx et al.
--------------------------------------------------------------------------------
4,767,609 Therapeutic and Diagnostic Processes Aug. 30, 1988
Using Isotope Transfer to Chelator-Target
Recognition Molecule Conjugate
Xxxxxx X. Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
4,772,548 Radioisotopicassay Using Isotope Transfer Sep. 20, 1988
to Chelator-Target Recognition Molecule
Conjugate
Xxxxxx X. Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
4,843,122 Detectable Molecules, Method of June 27, 1989
Preparation and Use
Xxxxxx X. Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
4,849,208 Detectable Molecules, Method of Jul. 18, 1989
Preparation and Use
Xxxxxx X. Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
- 1 -
================================================================================
Grant of
Patent
Patent Number Title/Inventor Issue Date
--------------------------------------------------------------------------------
4,849,505 Detectable Molecules, Method of Jul. 18, 1989
Preparation and Use
Xxxxxx X. Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
4,868,103 Analyte Detection by Means of Energy Sep. 19, 1989
Transfer
Xxxxxx X. Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
4,889,798 Heterologous System for the Detection of Dec. 26, 1989
Chemically Labeled DNA and other
Biological Materials Providing a Receptor or
Target Moiety Thereon
Xxxxxx Xxxxxxx
--------------------------------------------------------------------------------
4,894,325 Hybridization Method for the Detection of Jan. 16, 1990
Genetic Material
Xxxx Xxxxxxxxxx et al.
--------------------------------------------------------------------------------
4,900,659 Nucleotide Sequence Composition and Feb. 13, 1990
Method for Detection for Neissera
Gonorrhoeae and Method for Screening for
a Nucleotide Sequence that is Specific for
a Genetically Distinct Group
Xxxxxx Xx et al.
--------------------------------------------------------------------------------
4,943,523 Detectable Molecules, Method of Jul. 24, 1990
Preparation and Use
Xxxxxx X. Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
4,952,685 Detectable Molecules, Method of Aug. 28, 1990
Preparation and Use
Xxxxxx X. Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
4,987,065 In Vivo Labelling of Polynucleotide Jan. 22, 1991
Sequences
Xxxxxx X. Xxxxxxxxxxxxxxx et al.
--------------------------------------------------------------------------------
4,994,373 Method and Structures Employing Feb. 19, 1991
Chemically-Labelled Polynucleotide Probes
Xxxxxx X. Xxxxxxxxxxxxxxx et al.
--------------------------------------------------------------------------------
5,002,885 Detectable Molecules, Method of Mar. 26, 1991
Preparation and Use
Xxxxxx X. Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
5,013,831 Detectable Molecules, Method of May 7, 1991
Preparation and Use
Xxxxxx X. Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
5,024,933 Method and Kit for Sample Adherence to June 18, 1991
Test Substrate
Xxxx-Xxxx Yang et al.
--------------------------------------------------------------------------------
5,061,076 Time-Resolved Fluorometer Oct. 29, 1991
Xxx Xxxxxx
--------------------------------------------------------------------------------
- 2 -
================================================================================
Grant of
Patent
Patent Number Title/Inventor Issue Date
--------------------------------------------------------------------------------
5,082,830 End Labeled Nucleotide Probe Jan. 21, 1992
Xxxxxxxxx X. Xxxxxx et al.
--------------------------------------------------------------------------------
5,175,269 Compound and Detectable Molecules Dec. 29, 1992
Having An Oligo- or Polynucleotide with
Modifiable Reactive Group
Xxxxxx X. Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
5,241,060 Base Moiety-Labeled Detectable Nucleotide Aug. 31, 1993
Xxxx Xxxxxxxxxx et al.
--------------------------------------------------------------------------------
5,260,433 Saccharide Specific Binding System Nov. 9, 1993
Labeled Nucleotides
Xxxx Xxxxxxxxxx et al.
--------------------------------------------------------------------------------
5,288,609 Capture Sandwich Hybridization Method Feb. 22, 1994
and Composition
Xxxx Xxxxxxxxxx et al.
--------------------------------------------------------------------------------
5,328,824 Methods of Using Labeled Nucleotides Jul. 12, 1994
Xxxxx X. Xxxx
--------------------------------------------------------------------------------
Allowed claims (195-267) transmitted on
Feb. 6, 1995 to Amersham under
Confidientiality Agreement
================================================================================
- 3 -
================================================================================
Patent Number Publication Date
(Country) Title/Inventor of Patent Grant
--------------------------------------------------------------------------------
560 651 (Australia) Modified Nucleotides and Methods of Oct. 16, 1987 (16
Preparing and Using Same yr. term began Apr.
Xxxxx X. Xxxx et al. 13, 1982)
--------------------------------------------------------------------------------
1 219 824 (Canada) Modified Nucleotides and Methods of Mar. 31, 1987
Preparing and Using Same
Xxxxx X. Xxxx et al.
--------------------------------------------------------------------------------
1 223 831 (Canada) Modified Nucleotides, Methods of Jul. 7, 1987
Preparing and Utilizing and
Compositions Containing the Same
Xxxx X. Xxxxxxxxxx et al.
--------------------------------------------------------------------------------
EP 0 285 057 B1 Modified Nucleotides, Methods of May 10, 1988
Preparing and Utilizing and
Compositions Containing the Same
Xxxx X. Xxxxxxxxxx et al.
--------------------------------------------------------------------------------
EP 0 063 879 B1 Modified Nucleotides and Methods of Nov. 23, 1989
Preparing and Using Same
Xxxxx X. Xxxx et al.
--------------------------------------------------------------------------------
1,237,369 Visualization Polymers and Their May 31, 1988
Application to Diagnostic Medicine
Xxxxx X. Xxxx et al.
--------------------------------------------------------------------------------
1,254,525 Kit for Terminally Chemically Labeling May 23, 1989
DNA Xxxxxxxxx X. Xxxxxx et al.
--------------------------------------------------------------------------------
1,256,023 Method of Radioactively Labeling June 20, 1989
Diagnostic and Therapeutic Agents
Containing a Chelating Group
Xxxxxx Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
1,260,368 Composition and Method for the Sept. 26, 1989
Detection of the Presence of a
Polynucleotide Sequence of Interest
Xxxxxx Xxxxxxx et al.
--------------------------------------------------------------------------------
1,260,372 Hybridization Method for the Sept. 26, 1989
Detection of Genetic Materials
Xxxxxx Xxxxxxx et al.
================================================================================
- 4 -
================================================================================
Patent Number Publication Date
(Country) Title/Inventor of Patent Grant
--------------------------------------------------------------------------------
1,268,115 Method and Composition for Detecting April 24, 1990
Analyte Moieties
Xxxxxxx Xxxxxxxxxx
--------------------------------------------------------------------------------
1,281,283 (Canada) Method for Detecting an Analyte Moiety Mar. 12, 1991
by Means of Signal Localization
Xxxxxx Xxxxxxx
--------------------------------------------------------------------------------
1,285,330 Analyte Detection by Means of Energy June 25, 1991
Transfer Xxxxxx Xxxxxxxxxxxxxxx et al.
--------------------------------------------------------------------------------
1,288,811 Assay Method Utilizing Polynucleotide Nov. 3, 1987
Sequences
Xxxxxx Xxxxxxxxxx et al.
--------------------------------------------------------------------------------
EP 0 133 473 B1 In Vivo Labelling of Polynucleotide March 23, 1994
Sequences Xxxxxx Xxxxxxxxxxxxxxx et al.
--------------------------------------------------------------------------------
EP 0 173 339 B1 Composition and Method for the Jan. 22, 1992
Detection of the Presence of a
Polynucleotide Sequence of Interest
Xxxxxx Xxxxxxx et al.
--------------------------------------------------------------------------------
EP 0 212 546 B1 Method for Labeling Polynucleotide Apr. 1, 1992
Sequences
Xxxxxx Xxxxxxxxxxxxxxx et al.
--------------------------------------------------------------------------------
1,295,559 Method for Labeling Polynucleotide Feb. 11, 1992
Sequences
Xxxxxx Xxxxxxxxxxxxxxx et al.
--------------------------------------------------------------------------------
1,299,073 Nucleotide Sequence Composition Method Apr. 21, 1992
for Detection of Neisseria gonorrhoeae
and Method
(Canada) for Screening for a Nucleotide Sequence
that is Specific for a Genetically
Distinct Group
Xxxxxx Xx & Xxxx-Xxxx Xxxx
--------------------------------------------------------------------------------
1,309,672 Methods and Structures Employing Non- Nov. 3, 1992
Radioactive Chemically-Labeled
Polynucleotide Probes
Xxxxxx Xxxxxxxxxxxxxxx
================================================================================
- 5 -
================================================================================
Patent Number Publication Date
(Country) Title/Inventor of Patent Grant
--------------------------------------------------------------------------------
1,314,503 Detectable Moelcules, Method of March 16, 1993
Preparation And Use
Xxxxxx Xxxxxxxxxxxxxxx
--------------------------------------------------------------------------------
1,314,810 Heterologous System for the Detection March 23, 1993
of Chemically-Labeled DNA and Other
Biological Materials Providing a
Receptor or Target
Moiety Thereon
Xxxxxx Xxxxxxx
--------------------------------------------------------------------------------
EP 0 242 527 B1 Analyte Detection by Means of Energy May 13, 1992
Transfer
Xxxxxx Xxxxxxxxxxxxxxx et al.
--------------------------------------------------------------------------------
1,315,222 Polynucleotide Probes and a Method for March 30, 1993
Their Preparation
Xxxxx Xxx et al.
--------------------------------------------------------------------------------
0 149 654 B1 Detecting Agent Carrying Polymer Sep. 9, 1992
Having Multiple Units of Visualization
Monomer
Xxxxx X. Xxxx et al.
--------------------------------------------------------------------------------
EP 0 097 373 B1 Modified Nucleotides, Methods of Oct. 7, 1992
Preparing and Utilizing and
Compositions Containing the Same
Xxxx X. Xxxxxxxxxx et al.
--------------------------------------------------------------------------------
EP 0 212 670 B1 Method for Detecting an Analyte Moiety Nov. 4, 1992
by Means of Signal Localization
Xxxxxx Xxxxxxx
--------------------------------------------------------------------------------
EP 0 117 440 B1 Method and Structures Employing Apr. 7, 1993
Chemically-Labelled Polynucleotide
Probes
Xxxxxx X. Xxxxxxxxxxxxxxx et al.
--------------------------------------------------------------------------------
EP 0 244 860 B1 Polynucleotide Probes and a Method Apr. 7, 1993
for their Preparation
Xxxxx X. Xxx et al.
================================================================================
EP 0 343 424 B1 Method and Kit for Sample Adherence Apr. 21, 1993
to Test Substrate
Xxxx-Xxxx Yang et al.
================================================================================
- 6 -
================================================================================
Patent Number Publication Date
(Country) Title/Inventor of Patent Grant
--------------------------------------------------------------------------------
EP 0 159 719 B1 Hybridization Method for the Jun. 30, 1993
Detection of Genetic Material
Xxxx Xxxxxxxxxx et al.
--------------------------------------------------------------------------------
EP 0 122 614 B1 Kit for Terminally Chemically Jul. 14, 1993
Labelling DNA
Xxxxxxxxx Xxxxxx
--------------------------------------------------------------------------------
EP 0 150 844 B1 Method of Radioactively Labeling Jul. 28, 1993
Diagnostic and Therapeutic Agents
Containing a Chelating Group
Jannis Stavrianpoulos
--------------------------------------------------------------------------------
0 237 737 B1 A Composition Specific for Neisseria Sep. 8, 1993
Gonorrhoea
Xxxxxx Xx et al.
================================================================================
- 7 -
EXHIBIT B: Products and Transfer Price Paid by Amersham
*
----------
* The information omitted is confidential and has been filed separately with
the Commission pursuant to Rule 406.
- 1 -
*
PRICE INDEX 1995
IN SITU HYBRIDIZATION ASSAY SYSTEMS
Cat. No. Product Quantity Price
BioPap(TM) Kits for Detection of HPV on Cervical Smear Specimens
32881 BioPap Human papillomavirus DNA Assay for Cervical Smears 20 test kit $ 345.00
32892 BioPap Human papillomavirus DNA Typing Assay for
Cervical Specimens (Types 6/11, 16/18, 31/33/51 10 test kit 305.00
32883 BioPap Human Papillomavirus DNA Typing Assay
Certival Specimen Transport Kit for 10 specimen 35.00
PathoGene(R) Kits for Detection of HPV on Formalin-fixed, Paraffin-embedded Tissue Sections
32879 PathoGene in situ Screening Assay for Human Papillomavirus 20 test kit 425.00
32895 PathoGene in situ Typing Assay for Human Papillomavirus
(Types 6/11, 16/18, 31/33/51) 10 test kit 305.00
32877 PathoGene DNA Probe Assay for Identification of Human Papillomavirus
(Types 6/11, 16/18, 31/33/51 20 test kit 525.00
32878 PathoGene HPV 18 DNA Probe Reagent 1 ml 140.00
PathoGene(R) Kits for Detection of Infectious Agents on Formalin-fixed, Paraffin-embedded Tissue Sections
Peroxidase-AEC Substrate Detection Kits
32871 PathoGene DNA Probe Assay for Identification of Adenovirus
32872 PathoGene DNA Probe Assay for Identification of Cytomegalovirus 20 test kit 235.00
32873 PathoGene DNA Probe Assay for Identification of Xxxxxxx-Xxxx Virus 20 test kit 260.00
32874 PathoGene DNA Probe Assay for Identification of Hepatitis B Virus 20 test kit 235.00
32875 PathoGene DNA Probe Assay for Identification of Herpes Simplex Virus 20 test kit 235.00
32876 PathoGene DNA Probe Assay for Identification of Chlamydia trachomatis 20 test kit 235.00
Peroxidase-DAB Substrate Detection Kits
32861 PathoGene DNA Probe Assay for identification of 20 test kit 235.00
32862 PathoGene DNA Probe Assay for identification of 20 test kit 260.00
32863 PathoGene DNA Probe Assay for identification of 20 test kit 235.00
32864 PathoGene DNA Probe Assay for identification of 20 test kit 235.00
32865 PathoGene DNA Probe Assay for identification of 20 test kit 235.00
32866 PathoGene DNA Probe Assay for identification of 20 test kit 235.00
----------
* The information omitted is confidential and has been filed separately with
the Commission pursuant to Rule 406.
- 2 -
Alkaline Phosphatase-BCIP/NBT Substrate Detection Kit
32851 PathoGene DNA Probe Assay for identification of Adenovirus 20 test kit $250.00
32852 PathoGene DNA Probe Assay for identification of Cytomegalovirus 20 test kit 275.00
32853 PathoGene DNA Probe Assay for identification of Xxxxxxx-Xxxx Virus 20 test kit 250.00
32854 PathoGene DNA Probe Assay for identification of Hepatitus B Virus 20 test kit 250.00
32855 PathoGene DNA Probe Assay for identification of Herpes Simplex Virus 20 test kit 250.00
32856 PathoGene DNA Probe Assay for identification of Chlamydia trachomatis 20 test kit 250.00
IN SITU HYBRIDIZATION ASSAY SYSTEMS
Cat. No. Product Quantity Price
32870 Peroxidase-ABC Detection Kit (ready-to-use) 20 test kit 95.00
32860 Peroxidase-ABC Detection Kit (ready-to-use) 20 test kit 95.00
32850 Alkaline Phosphate-BCIP/NBT (ready-to-use) 20 test kit 105.00
32700 Enhanced in situ Detection Kit, alkaline phosphatase 20 test kit 195.00
32600 Enhanced in situ Detection Kit, peroxidase 20 test kit 195.00
IN SITU HYBRIDIZATION ASSAY SYSTEMS
Cat. No. Product Quantity Price
46305 Dot Blot Hybridization and Detection Assay Kit 1 kit 750.00
46305C Dot Blot Hybridization and Detection Assay Kit, Control DNA Pack 1 kit 170.00
46307 Dot Blot Hybridization and Detection Assay Kit, CMV Control DNA Pack 1 kit 135.00
46308 Dot Blot Hybridization and Detection Assay Kit, HBV Control DNA Pack 1 kit 135.00
44300 Dot Blot Manifold 1 unit 425.00
46330 HIV-1 Microplate Hybridization Assay 96 test kit 625.00
46331 SK 38K/SK 39 Oligonucleotide pair
complementary to HIV-1 gag region 5 nanomoles each 175.00
46340 MTB Microplate Hybridization Assay 96 test kit 625.00
46341 MTB 10/MTB 11 Oligonucleotide pair complementary to MTB 5 nanomoles each 175.00
46350 HBV Microplate Hybridization Assay 96 test kit 625.00
46351 HBO1/HBO2 Oligonucleotide pair
complementary to HBV core region 5 nanomoles each 175.00
46352 HBV Serum Specimen Preparation Kit for 96 specimens 50.00
46353 HBV Enhanced Microplate Hybridization Assay for 96 specimens 700.00
46354 HBV Serum Specimen Titration Standards for 4 assay determinations 50.00
46360 HIV-2 Microplate Hybridization Assay 96 test kit 625.00
46361 B306/VB310 Oligonucleotide pair complementary to HIV-2 5 nanomoles each 175.00
- 3 -
BIOPROBE(R) LABELED PROBES
Cat. No. Product Quantity Price
40834 Adenovirus 80ul $175.00
40835 Cytomegalovirus 80ul 205.00
00000 Xxxxxxx-Xxxx Virus 80ul 175.00
40837 Hepatitus B Virus 80ul 175.00
40838 Herpes Simplex Virus 80ul 175.00
00000 Xxxxxxxxx trachomatis 80ul 175.00
40840 Lambda 80ul 175.00
40841 pBR322 (negative DNA control) 80ul 75.00
40842 Hepatitis A Virus 80ul 175.00
40843 Mycoplasma pneymoniae 80ul 175.00
40845 SV40 80ul 175.00
00000 Xxxxxxxxxxxxx jejuni 80ul 175.00
40847 JC Virus 80ul 175.00
40848 BK Virus 80ul 175.00
40849 Blur 8 (human alu repeat) (positive DNA control) 80ul 75.00
40714 c-Ha-ras (activated, human) 80ul 220.00
40717 c-Myc (human) 80ul 220.00
40718 N-Myc (human) 80ul 220.00
BIOPROBE(R) LABELING SYSTEMS FOR NUCLEIC ACIDS
Cat. No. Product Quantity Price
42803 Nick Translation System (containing Bio II-dUTP) for 10u DNA 230.00
42804 Nick Translation System (to be used with nucleotide of choice) for 10u DNA 105.00
42809 Terminal Labeling Kit for 10u DNA 285.00
42810 Random Priming Kit (containing Bio 11-dUTP) for 10u DNA 230.00
42813 BioBridge Labeling System for 8u DNA 295.00
42814 BioBridge Lebaling Molecule for 8u DNA 210.00
42807 RNA Labeling System - T3/T7 for 20 reactions (1u each) 330.00
42808 RNA Labeling System - SP6 for 20 reactions (1u each) 330.00
BIOPROBE(R) LABELING SYSTEMS FOR NUCLEIC ACIDS - BIOTINYLATED NUCLEOTIDES
Cat. No. Product Quantity Price
42806 Bio-11dUTP (0.3 mM) 22.5 nanomoles 225.00
42806-50 Bio-11dUTP (1.0 mM) 50.0 nanomoles 285.00
42811 Bio-16dUTP (0.3 mM) 22.5 nanomoles 230.00
42811-50 Bio-16dUTP (1.0 mM) 50.0 nanomoles 285.00
42816 Bio-11dCTP (0.3 mM) 22.5 nanomoles 225.00
42816-50 Bio-11dCTP (1.0 mM) 50.0 nanomoles 285.00
42819 Bio-7-dATP (0.3 mM) 22.5 nanomoles 225.00
42819-50 Bio-71dATP (1.0 mM) 50.0 nanomoles 285.00
- 4 -
42812 Bio-AP3-dCTP (0.3 mM) 22.5 nanomoles $230.00
42815 Bio-11-CTP (20 mM) 1u mole 385.00
42801 Bio-11-CTP (20 mM) 1u mole 385.00
00000 Xxxxxxxxxx XXX (20 mM) 400 nanomoles 230.00
DETEK(R) SIGNAL GENERATING SYSTEMS
Cat. No. Product Quantity Price
43818* DETEK I-f for 200 slides 180.00
43861* IgG fraction rabbit anti-biotin 0.4 ml 210.00
43805* DETEK-fav 5 ml 110.00
43820* DETEK-hrp Kit 00 ml working solution or 150.00
40 membranes (100 cm2 each)
43822* DETEK-alk Kit 500 ml working solution or 225.00
40 membranes (100 cm2 each)
42823* DETEK Enhancer Kit for 20 slides 135.00
43825 Peroxidase Substrate Kit (AEC) 300 ml working solution 90.00
43826 Peroxidase Substrate Kit (DAB) 300 ml working solution 90.00
43827 Alkaline Phospharase Substrate Kit (NBT/BCIP) 400 ml working solution 160.00
43406 ENZOITIN(R)Biotinylating Reagent 100 mg 150.00
GLASS FIBER FILTERS
Cat. No. Product Quantity Price
44524 Disc (24 min diameter) 400/box 60.00
44525 Disc (25 min diameter) 400/box 60.00
44101 Rectangle (10.25 cm x 25.4 cm) 100/box 120.00
* These PRODUCTS are designated for nucleic acid detection
- 5 -
EXHIBIT C: AMERSHAM AFFILIATES
Australia: Amersham Australia Pty Ltd
00 Xxxxxx Xxxxxx
Xxxxxx Xxxx, Xxxxxx
XXX 0000
Xxxxxxxxx
Belgium: Amersham Belgium NV/SA
Xxxxxxxxxxxxxxxxx 000 X
0000 xxxx
Xxxxxxx
Xxxxxx: Amersham Canada Ltd
0000 Xxxxx Xxxxxxx Xxxx Xxxx
Xxxxxxxx
Xxxxxxx X0X 0X0
Xxxxxx
Denmark: Amersham Denmark ApS
Xxxxxxx 00
XX-0000 Xxxxxxxx
Xxxxxxx
France: Amersham France SA
12 Avenue des Xxxxxxxxx
XX Xxxxxxxxxxx
00000 Xxx Xxxx
Xxxxxx
Germany: Amersham Xxxxxxx
GmbH & Co KG
Geschaftsbereich Life Science
Xxxxxxxxx 0
X - 00000 Xxxxxxxxxxxx
Xxxxxxx
Xxxx Xxxx: Amersham Far East Trading Ltd
Suite 1001-7
Sun Hung Xxx Xxxxxx
00 Xxxxxxx Xxxx
Xxxxxxx, Xxxx Xxxx
Xxxxx: Amersham Italia S.r.L
Xxx Xxxxxxxxxxxx 00
00000 Xxxxxx
Xxxxx
- 1 -
Japan: Amersham KK
Tokyo Toyama Kaikan
1-3 Xxxxxxx 0-Xxxxx
Xxxxxx-Xx
Xxxxx 000
Xxxxx
Xxxxxxxxxxx: Amersham Nederland X.X
Xxxxxxxxxxxxx 0x
0000 XX'x Xxxxxxxxxxxxx
Xxxxxxxxxxx
Norway: Amersham Denmark Aps
Norway Branch
Xxxxxxxxxxxx 000
XX Xxx 000
X-0000 Xxxxxxx
Xxxxxx
Russia: Amersham International plc
Moscow Office
Xxxxxxxxx 00X, 0xx Xxxxx
Xxxxxx 000000, Xxxxxx
Xxxxx: Amersham Iberica S.A
Xxxxxxx Xxxxx 00-0x
00000 Xxxxxx
Xxxxx
Sweden: Amersham Sweden AB
Xxxxxxxxx 0X
000 00 Xxxxx
Xxxxxx
Xxxxxxxxxxx: Amersham Rahn
Xxxxxxxxxxxxx 000
XX-0000
Xxxxxx
Xxxxxxxxxxx
USA: Amersham North America
0000 Xxxxx Xxxxxxxxxx Xxxxx
Xxxxxxxxx Xxxxxxx
Xxxxxxxx 00000
- 2 -
EXHIBIT D: Component and transfer price paid by Enzo
*
----------
* The information omitted is confidential and has been filed separately with
the Commission pursuant to Rule 406.
- 1 -
EXHIBIT E: Component 1 and transfer price paid by Enzo
*
Patents licensed to Amersham International
================================================================================
Country Patent Number Inventor
--------------------------------------------------------------------------------
UK/Belgium/France/Germany/Italy/ EPO 116454 Xxxxxxxxx X.X. et al.
Netherlands/Sweden/Switzerland
--------------------------------------------------------------------------------
Australia 575552 Xxxxxxxxx X.X. et al.
--------------------------------------------------------------------------------
Canada 1217121 Xxxxxxxxx X.X. et al.
--------------------------------------------------------------------------------
Finland 76380 Xxxxxxxxx X.X. et al.
--------------------------------------------------------------------------------
Japan 1649 482 Xxxxxxxxx X.X. et al.
--------------------------------------------------------------------------------
New Zealand 207095 Xxxxxxxxx X.X. et al.
--------------------------------------------------------------------------------
South Africa 84/0909 Xxxxxxxxx X.X. et al.
--------------------------------------------------------------------------------
USA 4598044 Xxxxxxxxx X.X. et al.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Europe 120376 Xxxx M
--------------------------------------------------------------------------------
USA 5053326 Xxxx M
--------------------------------------------------------------------------------
Japan 1634268 Xxxx M
================================================================================
----------
* The information omitted is confidential and has been filed separately with
the Commission pursuant to Rule 406.
- 1 -
Exhibit F:
*
----------
* The information omitted is confidential and has been filed separately with
the Commission pursuant to Rule 406.
- 1 -
Exhibit G:
Product Safety Regulations
--------------------------
US: OSHA Hazard Communication Standards
UK: Chemical (Hazardous Information and Packaging)
Japan: Poisonous and Deleterious Substance Control Law
- 1 -
